{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:07:53Z","timestamp":1777900073071,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011025","name":"Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602165"],"award-info":[{"award-number":["81602165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["CE230100001"],"award-info":[{"award-number":["CE230100001"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ebiom.2026.106154","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:28:54Z","timestamp":1770773334000},"page":"106154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer"],"prefix":"10.1016","volume":"125","author":[{"given":"Changyuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita A.","family":"Busuttil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catriona A.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8031-9086","authenticated-orcid":false,"given":"Jiangning","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Boussioutas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger J.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib2","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9813","key":"10.1016\/j.ebiom.2026.106154_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib5","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ebiom.2026.106154_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102325","article-title":"Is there still a place for radiotherapy in gastric cancer?","volume":"68","author":"Chong","year":"2023","journal-title":"Curr Opin Pharmacol"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106154_bib7","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1200\/JCO.20.02761","article-title":"HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ Study","volume":"39","author":"Haffner","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106154_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN Clinical Practice Guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.annonc.2020.11.004","article-title":"Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial","volume":"32","author":"de Steur","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial\u2606","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106154_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2026.106154_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920930359","article-title":"A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer","volume":"12","author":"Wang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"7517","key":"10.1016\/j.ebiom.2026.106154_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41467-018-03121-2","article-title":"A proteomic landscape of diffuse-type gastric cancer","volume":"9","author":"Ge","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106154_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/1878-0261.13654","article-title":"Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer","volume":"18","author":"Hu","year":"2024","journal-title":"Mol Oncol"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106154_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053674","article-title":"Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review","volume":"11","author":"Glaab","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106154_bib18","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/SLA.0b013e31827c1180","article-title":"Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer","volume":"257","author":"Maak","year":"2013","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106154_bib19","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1158\/1078-0432.CCR-11-2956","article-title":"Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial","volume":"18","author":"Cheang","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib20","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1038\/s41467-021-25122-4","article-title":"Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts","volume":"12","author":"Na","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib21","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41467-018-04179-8","article-title":"Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype","volume":"9","author":"Oh","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(18)30108-6","article-title":"Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis","volume":"19","author":"Cheong","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106154_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/bjc.2014.639","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"112","author":"Collins","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib24","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1038\/s41467-022-33282-0","article-title":"Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106154_bib26","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1158\/1078-0432.CCR-13-3049","article-title":"A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response","volume":"20","author":"Busuttil","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","article-title":"Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil","volume":"145","author":"Lei","year":"2013","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"Database issue","key":"10.1016\/j.ebiom.2026.106154_bib29","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2026.106154_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.physa.2018.07.023","article-title":"Pareto's 80\/20 rule and the Gaussian distribution","volume":"510","author":"Tanabe","year":"2018","journal-title":"Physica A Stat Mech Appl"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106154_bib31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ebiom.2026.106154_bib32","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection","volume":"30","author":"Smalley","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106154_bib33","series-title":"Sample Size Calculations in Clinical Research","author":"Chow","year":"2007"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5230\/jgc.2017.17.e23","article-title":"Comparison of the differences in survival rates between the 7th and 8th editions of the AJCC TNM staging system for gastric adenocarcinoma: a single-institution study of 5507 patients in Korea","volume":"17","author":"Kim","year":"2017","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.ebiom.2026.106154_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221099227","article-title":"Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis","volume":"29","author":"Li","year":"2022","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1470-2045(24)00031-7","article-title":"Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study","volume":"25","author":"McPhail","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2026.106154_bib37","series-title":"Cancer Survival in England: Adult, Stage at Diagnosis and Childhood\u2013Patients Followed up to 2018","author":"John","year":"2019"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/cncr.27854","article-title":"Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials","volume":"119","author":"Hui","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1186\/s12885-024-13096-7","article-title":"Cancer care treatment attrition in adults: measurement approaches and inequities in patient dropout rates - a rapid review","volume":"24","author":"Shand","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(24)00032-9","article-title":"Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study","volume":"25","author":"McPhail","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106154_bib41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2011.04.042","article-title":"Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy","volume":"141","author":"Tan","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib42","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","article-title":"Optimized PD-L1 scoring of gastric cancer","volume":"24","author":"Schoemig-Markiefka","year":"2021","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106154_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief Bioinform"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106154_bib44","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202211017","article-title":"Computational estimation of quality and clinical relevance of cancer cell lines","volume":"18","author":"Trastulla","year":"2022","journal-title":"Mol Syst Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.molcel.2014.11.002","article-title":"Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis","volume":"57","author":"Stefely","year":"2015","journal-title":"Mol Cell"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106154_bib46","doi-asserted-by":"crossref","first-page":"23863","DOI":"10.1074\/jbc.M311919200","article-title":"Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase","volume":"279","author":"Mishra","year":"2004","journal-title":"J Biol Chem"},{"issue":"25","key":"10.1016\/j.ebiom.2026.106154_bib47","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1038\/s41388-021-01847-w","article-title":"Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53","volume":"40","author":"Malkomes","year":"2021","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.ebiom.2026.106154_bib48","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.1073\/pnas.1103350108","article-title":"Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells","volume":"108","author":"Ong","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","article-title":"Targeting CDK1 in cancer: mechanisms and implications","volume":"7","author":"Wang","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib50","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.7150\/thno.48112","article-title":"STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1\/ERK signaling pathway","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106154_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000293","article-title":"KALRN mutations promote antitumor immunity and immunotherapy response in cancer","volume":"8","author":"Li","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s10020-020-0146-6","article-title":"The role of RICTOR amplification in targeted therapy and drug resistance","volume":"26","author":"Zhao","year":"2020","journal-title":"Mol Med"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106154_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/biom11101418","article-title":"Nicotinamide N-Methyltransferase: an emerging protagonist in cancer macro(r)evolution","volume":"11","author":"Parsons","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ph16010094","article-title":"The implication of topoisomerase II inhibitors in synthetic lethality for cancer therapy","volume":"16","author":"Matias-Barrios","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106154_bib55","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/annonc\/mdr021","article-title":"Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer","volume":"22","author":"Iqbal","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib56","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.23.00971","article-title":"Open-Label, multicenter, randomized, biomarker-integrated umbrella trial for second-line treatment of advanced gastric cancer: K-Umbrella gastric cancer study","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"379","key":"10.1016\/j.ebiom.2026.106154_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106154_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049321","article-title":"Tissue transglutaminase constitutively activates HIF-1alpha promoter and nuclear factor-kappaB via a non-canonical pathway","volume":"7","author":"Kumar","year":"2012","journal-title":"PLoS One"},{"issue":"6_Supplement","key":"10.1016\/j.ebiom.2026.106154_bib60","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1158\/1538-7445.AM2024-5872","article-title":"Abstract 5872: CDK1-SOX9 axis contributes to chemotherapy resistance in gastric cancer","volume":"84","author":"Al-Mathkour","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112005","article-title":"CDK1 bridges NF-kappaB and beta-catenin signaling in response to H. pylori infection in gastric tumorigenesis","volume":"42","author":"Zhu","year":"2023","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106154_bib62","article-title":"Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma","volume":"4","author":"Lee","year":"2023","journal-title":"Cell Rep Med"},{"issue":"24","key":"10.1016\/j.ebiom.2026.106154_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246140","article-title":"Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes","volume":"20","author":"Tirpe","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib64","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1096\/fj.201802186R","article-title":"Hyaluronan-mediated motility receptor confers resistance to chemotherapy via TGFbeta\/Smad2-induced epithelial-mesenchymal transition in gastric cancer","volume":"33","author":"Zhang","year":"2019","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106154_bib65","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1159\/000490871","article-title":"Sensitization of gastric cancer cells to 5-FU by MicroRNA-204 through targeting the TGFBR2-Mediated epithelial to mesenchymal transition","volume":"47","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106154_bib66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/A:1026476801463","article-title":"5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene","volume":"2","author":"Osaki","year":"1997","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40643-021-00486-z","article-title":"Multi-omics analysis defines 5-fluorouracil drug resistance in 3D HeLa carcinoma cell model","volume":"8","author":"Wang","year":"2021","journal-title":"Bioresour Bioprocess"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106154_bib68","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/1078-0432.CCR-15-0876","article-title":"A Patient-Derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition","volume":"22","author":"Mak","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7667","key":"10.1016\/j.ebiom.2026.106154_bib69","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2026.106154_bib70","article-title":"Gastric cancer-epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: an updated review","volume":"41","author":"Mamun","year":"2024","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hernan","year":"2010","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106154_bib72","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.0022-202x.2001.01409.x","article-title":"The Bax\/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95\/Fas-mediated apoptosis","volume":"117","author":"Raisova","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106154_bib73","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2589-7500(22)00003-6","article-title":"The medical algorithmic audit","volume":"4","author":"Liu","year":"2022","journal-title":"Lancet Digit Health"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106154_bib74","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/S2589-7500(24)00224-3","article-title":"Tackling algorithmic bias and promoting transparency in health datasets: the STANDING together consensus recommendations","volume":"7","author":"Alderman","year":"2025","journal-title":"Lancet Digit Health"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:22:48Z","timestamp":1777630968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":73,"alternative-id":["S2352396426000356"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106154","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106154"}}